Trial Profile
Response to Neoadjuvant Treatment With Anti-aromatase Anastrozole and Anti-estrogen Fulvestrant: a Randomized Phase II Study in Postmenopausal Patients With Hormone-sensitive Non-metastatic Breast Cancer and an Exploratory Study of Molecular Signatures of Response
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary) ; Anastrozole
- Indications Breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms HORGEN
- 31 Jan 2020 Results of pooled analysis of HORGEN (NCT00871858) and CARMINA02 (NCT00629616) studies evaluating neoadjuvant anastrozole and fulvestrant efficacy for postmenopausal HR+/HER2- breast cancer patients published in the British Journal of Cancer
- 14 Jul 2015 Status changed from recruiting to completed, according to results published in the British Journal of Cancer.
- 14 Jul 2015 Results published in the British Journal of Cancer.